Background
The Emory Georgia Emerging Infections Program (GA EIP) HAIC component is part of a network of state health departments and academic medical centers using active population-based surveillance to track trends of Healthcare-Associated Infections (HAIs) and antibiotic resistance in the United States. At GA EIP, HAIC surveillance occurs in all 8 counties of Health District 3 (HD3) and encompasses a variety of pathogens.
Clostridioides difficile Infection (CDI)
GA EIP CDI surveillance monitors CDI incidence and disease trends in an effort to aid in identifying CDI risk factors and effective preventative and antibiotic stewardship measures. CDI surveillance is especially important as C. difficile is a leading cause of healthcare-associated infections.
GA EIP CDI incidence cases must:
- Have a positive C. difficile toxin or C. difficile toxic gene test
- Not have a positive test in the 8 weeks prior to initial collection date
- Be at least 1 year of age at the time of specimen collection
- Be a resident of HD3
Pathogens
- Clostridioides difficile
Staphylococcus aureus Bacteremia Infection Surveillance (SAB)
Georgia EIP began conducting invasive Staphylococcus aureus surveillance in 2005 as part of the national Emerging Infections Program. Today, surveillance is carried out in all 8 counties of Health District 3 (HD3), representing more than 4 million residents in the Atlanta metropolitan area and focuses specifically on capturing S. aureus isolated from blood only. The program monitors both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) infections, capturing cases that occur in the community as well as in health care settings. Data from Georgia contribute to national estimates of disease burden, help identify populations at increased risk, and inform prevention strategies to reduce the impact of S. aureus infections.
Pathogens
- Staphylococcus aureus (MRSA and MSSA)
Previous Surveillance
- From 2005 to 2025, the GA EIP conducted surveillance for all invasive S. aureus infections in Health District 3 (including infections isolated from non-blood sources)
Multi-site Gram-negative Surveillance Initiative (MuGSI)
GA EIP was one of the first sites to conduct MUGSI surveillance, which started in 2011. Now, it currently operates among 11 EIP sites across the United States, representing a population of up to 24 million people, as of 2025. The catchment area for this project varies by pathogen; CRE surveillance occurs in all 8 counties of Health District 3; ESBL-E surveillance occurs in Fulton County only. MuGSI surveillance includes urine and normally sterile sources for both CRE and ESBL-E isolates.
Pathogens
Carbapenem-Resistant Enterobacterales (CRE)
(AND Resistant to at least one carbapenem including ertapenem)
- Escherichia coli
- Enterobacter cloacae complex
- Klebsiella pneumoniae
- Klebsiella oxytoca
- Klebsiella aerogenes
Extended-Spectrum Beta-Lactamase Producing Enterobacterales (ESBL-E)
(AND Resistant to at least one extended-spectrum cephalosporin and non-resistant to all tested carbapenems)
- Escherichia coli
- Klebsiella pneumoniae
- Klebsiella oxytoca
Previous Surveillance
- From 2011-2025, MuGSI conducted surveillance for Carbapenem-Resistant Acinetobacter (CRAB)
- Acinetobacter baumannii non-susceptible to any carbapenem (excludes ertapenem)
- From 2024-2025, MuGSI conducted surveillance for Invasive Escherichia coli (iEC)
- Escherichia coli of any resistance phenotype from a normally sterile site
- From 2016-2018, MuGSI conducted surveillance for Carbapenem-Resistant Pseudomonas aeruginosa (CRPA)
Nontuberculous mycobacteria (NTM)
Pulmonary (pNTM) and extrapulmonary (eNTM) nontuberculous mycobacteria infections present significant clinical and public health challenges due to diagnostic complexity, prolonged treatment, and species‑specific antimicrobial susceptibility patterns. GAEIP initiated NTM surveillance in 2025, including cultures collected in 2024, to better characterize the epidemiology of NTM disease and inform prevention and control efforts. This surveillance aims to describe the epidemiology of pulmonary and extrapulmonary NTM, characterize NTM species by patient demographics and site of infection, assess microbiologic and antimicrobial susceptibility patterns of public health relevance, and evaluate the molecular epidemiology of NTM disease.
Pulmonary NTM surveillance is conducted in Fulton County and includes all lower respiratory specimens (e.g., sputum, bronchoalveolar lavage, lung tissue, tracheal aspirates, and bronchial washings).
Extrapulmonary NTM surveillance is performed throughout the eight counties of Health District 3 and covers all non‑pulmonary specimens, except for stool and rectal swab specimens.
Pathogens
- Nontuberculous Mycobacteria species - Excluded mycobacterial species: M. gordonae, M. paragordonae, M. tuberculosis complex, M. leprae, M. lepromatosis, and M. ulcerans